← All trials
NCT05701306
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2023
- Primary completion
- Jun 1, 2026
- Completion date
- Dec 31, 2027
- First posted
- Jan 27, 2023
- Last posted
- Mar 27, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.